GDS Holdings Limited Reports First Quarter 2024 Results
May 22, 2024 07:00 ET
|
GDS Holdings Limited
SHANGHAI, China, May 22, 2024 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS”, “GDSH” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of...
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
May 22, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage...
WalkMe Ltd. Announces First Quarter 2024 Financial Results
May 22, 2024 07:00 ET
|
WalkMe Inc.
1Q24 Revenue of $68.6 million at the high end of the guidance range. 1Q24 Non-GAAP Operating Income of $4.4 million or 6% compared to a loss of ($8.8) million or (13%) in 1Q23.Record high Free Cash...
Akoustis Completes Rollout of its XBAW® Design Updates
May 22, 2024 07:00 ET
|
Akoustis, Inc.
Charlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave...
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
May 22, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Invivyd Elects Two New Independent Members to its Board of Directors
May 22, 2024 07:00 ET
|
Invivyd
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024 07:00 ET
|
Achilles Therapeutics PLC
Research collaboration combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
May 22, 2024 07:00 ET
|
Atea Pharmaceuticals, Inc.
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A...
Lands' End Announces First Quarter 2024 Earnings Conference Call
May 22, 2024 06:45 ET
|
Lands' End, Inc.
DODGEVILLE, Wis., May 22, 2024 (GLOBE NEWSWIRE) -- Lands' End, Inc. (NASDAQ: LE) will host a conference call at 8:30 a.m. Eastern Time on Wednesday, June 5, 2024, to discuss its first quarter 2024...
PDD Holdings Announces First Quarter 2024 Unaudited Financial Results
May 22, 2024 06:30 ET
|
PDD Holdings Inc.
DUBLIN and SHANGHAI, May 22, 2024 (GLOBE NEWSWIRE) -- PDD Holdings Inc. (“PDD Holdings” or the “Company”) (NASDAQ: PDD), today announced its unaudited financial results for the first quarter ended...